title: Demethylation demystification.
abstract: The ability of the DNA methyltransferase inhibitors (DNMTi) to induce terminal differentiation in fibroblasts was first noted by Taylor and Jones in 1979; Silverman and Holland reported hematologic improvement in patients with myelodysplastic syndrome (MDS) in 1993. That azacitidine improves survival in patients with high-risk MDS and acute myeloid leukemia with MDS features compared with a combined comparator group of supportive care, low-dose cytarabine, and intensive cytarabine plus anthracycline, while inducing trilineage normalization in approximately 15% of patients makes the development of more potent, more specific drugs that behave like azacitidine imperative. The question is, how do the azanucleosides behave?
authors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
authors: Lauren
authors: L
authors: Suarez
authors: Steven D
authors: SD
authors: Gore
mesh_terms: D000818:Animals; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077209:Decitabine; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*
chemical_list: D000077209:Decitabine; D001374:Azacitidine